Icotrokinra vs. Deucravacitinib in Psoriasis: Unpacking the Results of the Phase 3 ICONIC-ADVANCE 1 and 2 Studies With Dr. Linda Stein Gold
Linda Stein Gold, MD, reviews data from the first reported head-to-head trials of icotrokinra, an investigational oral interleukin (IL)-23 blocker, vs. deucravacitinib (Sotyktu, BMS).